title: Squamous cell carcinoma of the subglottis.
abstract: METHODS
  A retrospective study over a 25-year period of patients with laryngeal carcinoma treated by the Department of Otolaryngology at Wake Forest University.
  
  
  METHODS
  The boundaries of the subglottis were defined as 5 mm below the free edge of the true vocal folds extending to the inferior border of the cricoid cartilage. All were staged according to American Joint Committee on Cancer: stages I and II were considered early and stages III and IV as late. Patients were grouped by treatment modality of surgery alone, surgery and radiotherapy, radiotherapy alone, and radiotherapy with surgical salvage.
  
  
  RESULTS
  Fifteen patients represented 1.4% (15/1098) of laryngeal cancers diagnosed within that period. All patients had squamous cell carcinoma of the subglottis of which 20% (3/15) had early-stage disease (T1-T2) and 80% (12/15) had late-stage disease (T3-T4). Overall 3-year survival was low (25%) and is attributed to a high incidence of advanced-stage disease with a high rate of extralaryngeal spread and/or metastasis, especially to the lungs and paratracheal nodes.
  
  
  CONCLUSIONS
  To improve earlier detection by primary care physicians and otolaryngologists and to improve treatment outcome, awareness of subglottic carcinoma and its appropriate evaluation is critical in the patient presenting with hoarseness and/or stridor. Radiation therapy treatment to include the low and upper mediastinal compartments to cover local/regional extralaryngeal involvement is advocated as well as paratracheal lymphatic neck dissection and thyroidectomy in surgically treated lesions.
authors.affiliation: Ocshner Clinical Foundation, New Orleans, LA, USA. jgaras@ocshner.org
authors.forename: Jimmy
authors.initials: J
authors.lastname: Garas
authors.forename: W Fred
authors.initials: WF
authors.lastname: McGuirt
mesh_terms: D000328:Adult; D000368:Aged; D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005931:Glottis / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D007825:Laryngectomy / Q000379:methods; D007828:Laryngoscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome